⏳ Fetching live dividend data...
Home › Calculator › CMRX Dividend Calculator 2026
Chimerix, Inc. · NASDAQ
Price: $8.54 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in CMRX → $2828392.22M in 10 years · $234,720,584,979.92/month
Chimerix, Inc. operates as a biopharmaceutical company, committed to advancing therapeutic solutions that improve the lives of individuals grappling with severe medical conditions. Its sole approved medicine is TEMBEXA (brincidofovir), a lipid conjugate designed to combat smallpox by inhibiting viral DNA synthesis, positioned as a critical medical countermeasure. Beyond its commercial offering, Chimerix boasts a robust clinical-stage pipeline: ONC201 targets recurrent diffuse midline glioma in patients whose tumors possess the H3 K27M mutation. ONC206, an imipridone, is a Phase I candidate for solid tumors, functioning as both a Dopamine Receptor D2 (DRD2) antagonist and a caseinolytic protease P (ClpP) agonist. Notably, it exhibits superior non-competitive antagonism of DRD2 compared to ONC201. ONC212, another imipridone, acts as an agonist for the orphan G protein-coupled receptor (GPCR) tumor suppressor GPR132 and ClpP. This compound is being explored for a range of solid tumors and blood cancers, including pancreatic cancer and leukemias. dociparstat sodium (DSTAT) aims to overcome chemotherapy resistance in acute myeloid leukemia (AML) by inhibiting crucial proteins found in leukemic blasts and stem cells. Chimerix has also forged strategic partnerships, including licensing agreements with: The Biomedical Advanced Research and Development Authority (BARDA) for brincidofovir's smallpox treatment development. Cantex Pharmaceuticals, Inc. for the development and commercialization of a glycosaminoglycan compound. SymBio Pharmaceuticals for the development, manufacturing, and commercialization of BCV (brincidofovir) across multiple human indications. Established in 2000, Chimerix, Inc. maintains its headquarters in Durham, North Carolina.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CMRX position with:
Real after-tax yield depends on where you live and how you hold CMRX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 23.42% | 20.62% | $2,342 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 19.91% | 17.11% | $1,991 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 18.74% | 15.94% | $1,874 / yr |
| 🇬🇧 UK ISA | 0% | 23.42% | 20.62% | $2,342 / yr |
| 🇬🇧 UK Taxable | 8.75% | 21.37% | 18.57% | $2,137 / yr |
| 🇨🇦 TFSA | 0% | 23.42% | 20.62% | $2,342 / yr |
| 🇨🇦 CA Taxable | 25% | 17.57% | 14.77% | $1,757 / yr |
| 🇦🇺 Super (pension) | 15% | 19.91% | 17.11% | $1,991 / yr |
| 🇦🇺 AU Taxable | 30% | 16.39% | 13.59% | $1,639 / yr |
| 🇩🇪 DE Taxable | 26.375% | 17.24% | 14.44% | $1,724 / yr |
| 🇫🇷 FR Taxable | 30% | 16.39% | 13.59% | $1,639 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
CMRX pays quarterly — 4 times per year. Next ex-div: TBD.
How CMRX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CMRX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| D-Return | 2025-04-21 | 60,000 | $0.89 | $53.4K | ||
| D-Return | 2025-04-21 | 60,000 | $1.39 | $83.4K | ||
| D-Return | 2025-04-21 | 35,000 | $7.84 | $274.4K | ||
| D-Return | 2025-04-21 | 50,000 | $1.82 | $91.0K | ||
| D-Return | 2025-04-21 | 60,000 | $8.22 | $493.2K | ||
| D-Return | 2025-04-21 | 233,413 | $8.55 | $2.00M | ||
| D-Return | 2025-04-21 | 60,000 | $0.89 | $53.4K | ||
| D-Return | 2025-04-21 | 1,150,000 | $2.09 | $2.40M | ||
| D-Return | 2025-04-21 | 632,500 | $2.08 | $1.32M | ||
| D-Return | 2025-04-21 | 700,000 | $9.28 | $6.50M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CMRX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Chimerix, Inc. (CMRX) is currently trading at $8.54, 14% below its 52-week high. The current dividend yield is 23.42% based on an annual payout of $2.00 per share.
Chimerix, Inc. (CMRX) is a healthcare stock currently trading at $8.54 with a dividend yield of 23.42%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →